Sugi Predict

Sugi Predict / Targets / CD40LG

CD40LG

CD40 ligand · P29965 · CD40LG on Sugi Atlas →

3,866 patent compounds predicted against CD40LG, 2,710 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL3297268 SCHEMBL3297268 0.64 3/20
SCHEMBL6242038 SCHEMBL6242038 0.61 3/20
SCHEMBL6210682 SCHEMBL6210682 0.49 3/20
SCHEMBL6363338 SCHEMBL6363338 0.48 3/20
SCHEMBL6214268 SCHEMBL6214268 0.48 3/20
SCHEMBL6208823 SCHEMBL6208823 0.46 3/20
SCHEMBL6911279 SCHEMBL6911279 0.45 3/20
SCHEMBL6210121 SCHEMBL6210121 0.43 3/20
SCHEMBL6209628 SCHEMBL6209628 0.42 3/20
SCHEMBL7522280 SCHEMBL7522280 0.41 3/20
SCHEMBL1340222 SCHEMBL1340222 0.62 2/20
SCHEMBL7224470 SCHEMBL7224470 0.59 2/20
SCHEMBL10398604 SCHEMBL10398604 0.59 2/20
SCHEMBL10413972 SCHEMBL10413972 0.57 2/20
SCHEMBL10035677 SCHEMBL10035677 0.52 2/20
SCHEMBL9303113 SCHEMBL9303113 0.51 2/20
SCHEMBL9820416 SCHEMBL9820416 0.51 2/20
SCHEMBL9820417 SCHEMBL9820417 0.51 2/20
SCHEMBL9225420 SCHEMBL9225420 0.50 2/20
SCHEMBL7222842 SCHEMBL7222842 0.49 2/20

Clinical trials — most relevant to CD40LG by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Belatacept 3 Month Post Transplant Conversion Study PHASE4COMPLETED
Efficacy and Safety of Abatacept in Patients With Primary Sjögren's Syndrome PHASE3COMPLETED
Efficacy and Safety of Platelet-rich Plasma, Metformin and Cryotherapy in Treatment of Non-genital Warts PHASE2/PHASE3NOT_YET_RECRUITING
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma PHASE1/PHASE2COMPLETED
Phase I/IIa AdCD40L Immunogene Therapy for Malignant Melanoma and Other Solid Tumors PHASE1/PHASE2COMPLETED
Single-step Antigen Loading and TLR Activation of Dendritic Cells in Melanoma Patients PHASE1/PHASE2COMPLETED
Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic Melanoma PHASE1/PHASE2WITHDRAWN
BG9588 (Anti-CD40L Antibody) to Treat Lupus Nephritis PHASE2COMPLETED
Pilot Study Related to the Effect of Clopidogrel on Plasmatic Soluble CD40 Ligand During Systemic Lupus Erythematous PHASE1/PHASE2COMPLETED
COVID-19 Booster and IIV Schedule in Immunocompromised Hosts PHASE2RECRUITING
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer PHASE2RECRUITING
A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC) PHASE1/PHASE2RECRUITING
a Single Arm, Phase II Multicenter Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of Iparomlimab and Tuvonralima b and Chemotherapy ± Bevacizumab Induction Therapy Followed by Concurrent Chemoradiotherapy in Patients With Advanced Cervical Cancer . PHASE2NOT_YET_RECRUITING
Denosumab and Nivolumab Combination As 2d-line Therapy in Stage IV NSC Lung Cancer with Bone Metastases (DENIVOS) PHASE2COMPLETED
Treatment of B-Chronic Lymphocytic Leukemia (B-CLL) With Autologous CD40 Ligand and IL-2-Expressing Tumor Cells PHASE1COMPLETED
Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment PHASE1RECRUITING
A Phase I Study Of Thymoglobulin In Patients With Relapsed Or Refractory Multiple Myeloma PHASE1COMPLETED
CD40 Agonist and PD-1 Inhibitor in HNSCC PHASE1ACTIVE_NOT_RECRUITING
Dose Escalation Trial of CD40.HIVRI.Env Vaccine Combined or Not With a DNA-HIV-PT123 HIV-1 Vaccine in Healthy Volunteers PHASE1COMPLETED
A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35) PHASE1COMPLETED
CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease PHASE1COMPLETED
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors PHASE1ACTIVE_NOT_RECRUITING
Study of the CD40 Agonistic Monoclonal Antibody APX005M PHASE1COMPLETED
Autologous Dendritic Cell Therapy for Type 1 Diabetes Suppression: A Safety Study PHASE1COMPLETED
Using of Costimulatory and co Inhibatory Immune Checkpoints as Diagnostic and Prognostic in Breast Cancer nanUNKNOWN
Correlation Between Serum Markers of Unstable Plaque and Virtual Histology of Unstable Plaque Visualized by IVUS nanCOMPLETED
Role of Altered CD40-Ligand Gene Transcription in Systemic Lupus Erythematosus nanUNKNOWN
Role of CD11a in Pathogenesis of Primary ITP and Effect of Immunosuppressive Therapy on Its Level nanCOMPLETED
Novel Biomarkers in Inflammatory Bowel Disease nanCOMPLETED
Peptide-drug-conjugates for Personalized, Targeted Therapy of Chronic Lymphocytic Leukemia nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a CD40LG binder may also engage these)

ProteinNameSimilarity
P63304 — 1.000 P63304 →
P63305 — 1.000 P63305 →
Q9BDN3 — 1.000 Q9BDN3 →
Q9BDM3 — 1.000 Q9BDM3 →
P51749 — 1.000 P51749 →
P27548 — 1.000 P27548 →
Q9Z2V2 — 1.000 Q9Z2V2 →
Q95MQ5 — 1.000 Q95MQ5 →
O97605 — 1.000 O97605 →
O97626 — 1.000 O97626 →
Q9BDM7 — 1.000 Q9BDM7 →
Q9I8D8 — 1.000 Q9I8D8 →
P06804 — 0.993 P06804 →
P36939 — 0.993 P36939 →
P23383 — 0.993 P23383 →
Q1G1A2 — 0.993 Q1G1A2 →
Q75N23 — 0.992 Q75N23 →
TNFSF10 Tumor necrosis factor ligand superfamily member 10 0.992 landscape →
O77764 — 0.992 O77764 →
P79374 — 0.992 P79374 →
P51742 — 0.991 P51742 →
P23563 — 0.991 P23563 →
P16599 — 0.991 P16599 →
P59693 — 0.991 P59693 →
P50592 — 0.991 P50592 →
Q539C2 — 0.990 Q539C2 →
Q8WNR1 — 0.990 Q8WNR1 →
Q9BEA1 — 0.990 Q9BEA1 →
P13296 — 0.989 P13296 →
Q8JFG3 — 0.989 Q8JFG3 →